First Authorization for the combination of chondroitin and glucosamine
Bioiberica Farma, the Spanish division of Bioiberica, has received approval for the combination of chondroitin and glucosamine in Spain. This is the first authorization of its kind in Europe.
Bioiberica Farma specializes in the research and development of effective drugs that provide the best therapeutic alternatives in chondroprotection to prevent, delay, stabilize and repair and revert cartilage, synovial membrane and subchondral bone injuries.
Bioiberica Farma currently markets three chondroprotective drugs in Spain indicated for the treatment of osteoarthritis: chondroitin sulfate, glucosamine sulfate and hyaluronic acid.
Approval for the combination of chondroitin and glucosamine makes it possible to launch a new treatment based on the therapeutic synergy between the two active ingredients. The new treatment complements the current options available because it is particularly indicated as an attack treatment in patients with very limited functional capacity.
